TY - JOUR
T1 - Diagnosis and management of chronic myeloid leukemia
T2 - A survey of American and European practice patterns
AU - Kantarjian, Hagop M.
AU - Cortes, Jorge
AU - Guilhot, François
AU - Hochhaus, Andreas
AU - Baccarani, Michele
AU - Lokey, Lee
PY - 2007/4/1
Y1 - 2007/4/1
N2 - BACKGROUND. The success of imatinib therapy for chronic myeloid leukemia (CML) has brought new challenges; these include optimizing disease monitoring, imatinib resistance, and use of novel, more potent tyrosine kinase inhibitors. Thus, there is a need to establish new best practices for CML management in the post-imatinib era. METHODS. An internet-based questionnaire, consisting of 26 multiple choice questions, was developed to assess hematologists' and oncologists' self-reported treatment strategies for CML. RESULTS. Between November 2005 and January 2006, 956 eligible physicians responded to the survey; 727 from the US and 229 from Europe. Most US respondents (60%) practiced in the community setting, whereas European respondents were primarily academic (44%) and hospital-based (40%). Physicians' responses were generally in line with current recommendations, although differences were identified. Confusion existed among respondents over optimal timing of treatment decisions, with a notable proportion of physicians focusing on a single timepoint rather than consistent monitoring, as currently advocated. Some respondents were unaware of new molecular monitoring techniques, when to monitor for BCR-ABL mutations (and the impact on treatment decisions), and the benefit of new tyrosine kinase inhibitors. CONCLUSIONS. Responses to the survey suggest that treatment practices in some areas of CML management are not in line with current recommendations. Identified areas of need should be targeted in future educational activities for the CML community.
AB - BACKGROUND. The success of imatinib therapy for chronic myeloid leukemia (CML) has brought new challenges; these include optimizing disease monitoring, imatinib resistance, and use of novel, more potent tyrosine kinase inhibitors. Thus, there is a need to establish new best practices for CML management in the post-imatinib era. METHODS. An internet-based questionnaire, consisting of 26 multiple choice questions, was developed to assess hematologists' and oncologists' self-reported treatment strategies for CML. RESULTS. Between November 2005 and January 2006, 956 eligible physicians responded to the survey; 727 from the US and 229 from Europe. Most US respondents (60%) practiced in the community setting, whereas European respondents were primarily academic (44%) and hospital-based (40%). Physicians' responses were generally in line with current recommendations, although differences were identified. Confusion existed among respondents over optimal timing of treatment decisions, with a notable proportion of physicians focusing on a single timepoint rather than consistent monitoring, as currently advocated. Some respondents were unaware of new molecular monitoring techniques, when to monitor for BCR-ABL mutations (and the impact on treatment decisions), and the benefit of new tyrosine kinase inhibitors. CONCLUSIONS. Responses to the survey suggest that treatment practices in some areas of CML management are not in line with current recommendations. Identified areas of need should be targeted in future educational activities for the CML community.
KW - BCR-ABL mutation
KW - CML
KW - Clinical practice
KW - Dasatinib
KW - Imatinib
KW - Molecular monitoring
KW - Survey
UR - http://www.scopus.com/inward/record.url?scp=33947496833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947496833&partnerID=8YFLogxK
U2 - 10.1002/cncr.22523
DO - 10.1002/cncr.22523
M3 - Article
C2 - 17326047
AN - SCOPUS:33947496833
SN - 0008-543X
VL - 109
SP - 1365
EP - 1375
JO - Cancer
JF - Cancer
IS - 7
ER -